EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Oncology

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2013.49.5697PMID 24752053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?

  2014cited by this paper
• How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?

  2013cited by this paper
• EGFR mutations in squamous cell lung cancer in never-smokers.

  2013cited by this paper
• Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component

  2012cited by this paper
• Retrospective study of erlotinib in patients with advanced squamous lung cancer.

  2012cited by this paper
• Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

  2012cited by this paper
• Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

  2012cited by this paper
• Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.

  2012cited by this paper
• The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.

  2012cited by this paper
• &Dgr;Np63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach

  2012cited by this paper
• Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.

  2011cited by this paper
• Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.

  2011cited by this paper
• Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.

  2007cited by this paper
• Treatment of advanced non-small cell lung cancer

  2002cited by this paper

• Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

  2020cites this paper
• Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer

  2020influential citation
• Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma.

  2019cites this paper
• Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients

  2019cites this paper
• Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report

  2019cites this paper
• T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations

  2018cites this paper
• Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

  2018cites this paper
• High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

  2018cites this paper
• Hyper expression of MTBP may be an adverse signal for the survival of some malignant tumors

  2018cites this paper
• Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis

  2017cites this paper
• Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

  2017cites this paper
• Targeting the EGFR T790M mutation in non-small-cell lung cancer

  2017cites this paper
• Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

  2016cites this paper
• Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

  2015cites this paper
• Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

  2015cites this paper
• Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples

  2015cites this paper